Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation
Olivier Hanon,Jean-Sébastien Vidal,George Pisica-Donose,Galdric Orvoën,Jean-Philippe David,Edouard Chaussade,Laure Caillard,Laura W de Jong,Nicolas Boulloche,Ulric Vinsonneau,Stéphane Bouée,Pierre Krolak-Salmon,Laurent Fauchier,Pierre Jouanny,Guillaume Sacco,Fabienne Bellarbre,Joël Belmin,François Puisieux,Matthieu Lilamand,Elena Paillaud,Anne Sophie Boureau,SAFIR study group,Anne-Sophie Boureau,Gilles Berrut,Orvoën Galdric,Édouard Chaussade,Olivier Villejoubert,Thierry Joseph,Alain Pinzani,Dominique Mottier,Olivier Trinh,Clémence Boully,Émilie Crawford-Achour,Gregoire Range,Xavier Galimard,Thierry Le Maitre,Olivier Guerin,Marc Bonnefoy,Isabelle Mahe,Yasmina Boudali,Anne-Marie Hallet-Lezy,Olivier Toulza,Mathieu Debray,Naceur Aimouch,Gilles Barone-Rochette,Xavier Routon,Karim Chachoua,Martine Merceron,Hermine Lenoir,Éric Assemat,Amélie Delcourt,Marc Paccalin,Agnès Dauffy-Allain,Évelyne Mage,Jean-Marc Michel,Emmanuelle Duron-Garnier,Delphine Dubail,Yara Antakly-Hanon,Youssef Alaoui,Florence Cayre-Portron,Pascal Poncelet,Ileana Desormais,Jean-Claude Deharo,Laure Joly,Florian Labourée,Hélène Anard-Michelot,Patrick Friocourt,Aminata Diop,Anne Chahwakilian,Mohammed Kerzazi,Pierre-Emmanuel Cailleaux,Nicolas Roche,Brigitte Standish-Chesnel,Jérémie Despres,Sybile Lambert,Patrick Mismetti
DOI: https://doi.org/10.1136/heartjnl-2020-317923
IF: 5.7
Heart
Abstract:Objective: Direct oral anticoagulants have been evaluated in the general population, but proper evidence for their safe use in the geriatric population is still missing. We compared the bleeding risk of a direct oral anticoagulant (rivaroxaban) and vitamin K antagonists (VKAs) among French geriatric patients with non-valvular atrial fibrillation (AF) aged ≥80 years. Methods: We performed a sequential observational prospective cohort study, using data from 33 geriatric centres. The sample comprised 908 patients newly initiated on VKAs between September 2011 and September 2014 and 995 patients newly initiated on rivaroxaban between September 2014 and September 2017. Patients were followed up for up to 12 months. One-year risks of major, intracerebral, gastrointestinal bleedings, ischaemic stroke and all-cause mortality were compared between rivaroxaban-treated and VKA-treated patients with propensity score matching and Cox models. Results: Major bleeding risk was significantly lower in rivaroxaban-treated patients (7.4/100 patient-years) compared with VKA-treated patients (14.6/100 patient-years) after multivariate adjustment (HR 0.66; 95% CI 0.43 to 0.99) and in the propensity score-matched sample (HR 0.53; 95% CI 0.33 to 0.85). Intracerebral bleeding occurred less frequently in rivaroxaban-treated patients (1.3/100 patient-years) than in VKA-treated patients (4.0/100 patient-years), adjusted HR 0.59 (95% CI 0.24 to 1.44) and in the propensity score-matched sample HR 0.26 (95% CI 0.09 to 0.80). Major lower bleeding risk was largely driven by lower risk of intracerebral bleeding. Conclusions: Our study findings indicate that bleeding risk, largely driven by lower risk of intracerebral bleeding, is lower with rivaroxaban than with VKA in stroke prevention in patients ≥80 years old with non-valvular AF.